Form S-1

SenesTech, Inc. Announces Pricing of $5.0 Million Public Offering

Retrieved on: 
Monday, November 27, 2023
Sale, Research, Security (finance), Form, Investment, Exercise, SEC filing, Public expenditure, SenesTech, Prospectus, Form S-1, SNES, 3rd Floor

The Series Warrants have an exercise price of $1.30 per share and will be immediately exercisable upon issuance.

Key Points: 
  • The Series Warrants have an exercise price of $1.30 per share and will be immediately exercisable upon issuance.
  • The closing of the offering is expected to occur on or about November 30, 2023, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to the Company from the offering are expected to be approximately $5.0 million, before deducting the placement agent's fees and other offering expenses payable by the Company.
  • The public offering is being made only by means of a prospectus, which forms a part of the effective registration statement.

ALSP Orchid Acquisition Corporation I Announces it Will Redeem its Public Shares and Will Not Consummate an Initial Business Combination

Retrieved on: 
Wednesday, November 8, 2023
Science, Venture Capital, Biotechnology, Research, Pharmaceutical, Finance, Health, Professional Services, Transfer, IPO, Commission, Tax, Accounting, Form S-1, Form, Wind, Electric Bond and Share Company v. Securities and Exchange Commission, Bank statement, Finance Secretary (India), Trust, Interest on Lawyer Trust Accounts, Extension, ALSP, Articles of association, Security (finance), Article

As stated in the Company’s Articles and in the Company’s registration statement on Form S-1 (Registration No.

Key Points: 
  • As stated in the Company’s Articles and in the Company’s registration statement on Form S-1 (Registration No.
  • The per-share redemption price for the Public Shares will be approximately $10.86 (the “Redemption Amount”).
  • The Redemption Amount will be payable to the holders of the Public Shares upon delivery of their shares or units to the Company’s transfer agent, Continental Stock Transfer & Trust Company.
  • Beneficial owners of Public Shares held in “street name,” however, will not need to take any action in order to receive the Redemption Amount.

Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering

Retrieved on: 
Tuesday, October 31, 2023
Suite, Sale, Free File, Security (finance), Park Avenue, Form S-1, Form, Prospectus, DSM-IV codes, ATTN:, Therapy

MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the pricing of its public offering of an aggregate of 16,633,400 units at a public offering price of $0.3006 per unit.

Key Points: 
  • MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the pricing of its public offering of an aggregate of 16,633,400 units at a public offering price of $0.3006 per unit.
  • The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $5.0 million.
  • Maxim Group LLC and Lake Street Capital Markets, LLC are acting as placement agents for the offering.
  • The offering is being made only by means of a prospectus which is a part of the effective registration statement.

Nxu, Inc. Announces Closing of $3.0 Million Public Offering of Common Stock

Retrieved on: 
Monday, October 23, 2023
Sale, SEC filing, Security (finance), Park Avenue, EV, Telephone, Form S-1, Form, Attention, Prospectus

The gross proceeds of the offering to the Company, before deducting placement agent fees and commissions and other offering expenses, were approximately $3.0 million.

Key Points: 
  • The gross proceeds of the offering to the Company, before deducting placement agent fees and commissions and other offering expenses, were approximately $3.0 million.
  • Maxim Group LLC acted as the sole placement agent in connection with the offering.
  • The offering was conducted pursuant to the Company's registration statement on Form S-1, as amended, (File No.
  • A final prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov .

Urgently Announces Successful Closing of Merger With Otonomo Technologies & Effectiveness of S-1 Registration Statement

Retrieved on: 
Thursday, October 19, 2023
Software, Automotive, Artificial Intelligence, Other Transport, Technology, Apps, Applications, General Automotive, Transport, Registration statement, Insurance, Register, Sale, Security (finance), Form S-1, Form, Cyprus Securities and Exchange Commission, Original equipment manufacturer, Acquisition, Ridesharing, Prospectus, Ecosystem, Partnership, Service, Cryptocurrency

Urgent.ly, Inc. (“Urgently”), a U.S.-based leading provider of digital roadside and mobility assistance technology and services, today announced the closing of its acquisition of Otonomo Technologies Ltd. (“Otonomo”).

Key Points: 
  • Urgent.ly, Inc. (“Urgently”), a U.S.-based leading provider of digital roadside and mobility assistance technology and services, today announced the closing of its acquisition of Otonomo Technologies Ltd. (“Otonomo”).
  • In addition, Urgently’s registration statement on Form S-1 (the “Registration Statement”) has been declared effective by the U.S. Securities and Exchange Commission (the “SEC”).
  • Urgently anticipates its common stock will begin trading with Nasdaq under the ticker symbol “ULY” later today.
  • The Registration Statement has been filed with the Securities and Exchange Commission and became effective today.

Intelligent Bio Solutions Inc. Announces Closing of $4.378 Million Underwritten Public Offering Including Partial Exercise of Underwriters’ Overallotment Option

Retrieved on: 
Wednesday, October 4, 2023
Exercise, Unit, Common stock, Fifth Avenue, Certificate, Bangladesh Securities and Exchange Commission, Sale, Prospectus, Form S-1, Preferred stock, Series, Ladenburg Thalmann, Warrant, 4th floor, Form, Security (finance), Common

Ladenburg Thalmann & Co. Inc. acted as the sole bookrunning manager for the offering.

Key Points: 
  • Ladenburg Thalmann & Co. Inc. acted as the sole bookrunning manager for the offering.
  • Each Unit consists of one share of Common Stock (or one share of Preferred Stock), one Series E Warrant and one Series F Warrant.
  • The Units were priced at a combined public offering price of $0.55 per Unit for initial gross proceeds of approximately $4.378 million, before underwriting discounts and commissions and offering expenses.
  • The Company intends to use the net proceeds from this offering for general corporate purposes and working capital.

Intelligent Bio Solutions Inc. Announces Pricing of $4,000,000 Underwritten Public Offering

Retrieved on: 
Monday, October 2, 2023
Exercise, Unit, Common stock, Fifth Avenue, Certificate, Securities and Exchange Commission (Nigeria), Sale, Prospectus, Form S-1, Series, Ladenburg Thalmann, Warrant, 4th floor, Form, Security (finance), Preferred stock, Common

NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the pricing of an underwritten public offering of units (the “Units”) for gross proceeds of approximately $4.0 million.

Key Points: 
  • NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the pricing of an underwritten public offering of units (the “Units”) for gross proceeds of approximately $4.0 million.
  • The offering is expected to close on or about October 4, 2023, subject to customary closing conditions.
  • The Units were priced at a combined public offering price of $0.55 per Unit for initial gross proceeds of approximately $4.0 million, before underwriting discounts and commissions and offering expenses.
  • The Company intends to use the net proceeds from this offering for general corporate purposes and working capital.

Bluescape Opportunities Acquisition Corp. Will Redeem its Public Shares and Will Not Consummate an Initial Business Combination

Retrieved on: 
Friday, September 29, 2023
Professional Services, Finance, Transfer, Commission, Trust, Bangladesh Securities and Exchange Commission, Accounting, Wind, Form S-1, Acquisition, Interest on Lawyer Trust Accounts, Form, Finance Secretary (India), NYSE, Articles of association, Security (finance)

The Company will not consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association (the “Articles”).

Key Points: 
  • The Company will not consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association (the “Articles”).
  • As stated in the Company’s Articles and in the Company’s registration statement on Form S-1 (Registration No.
  • The per-share redemption price for the Public Shares will be approximately $10.04 (the “Redemption Amount”).
  • As of the close of business on October 30, 2023, the Public Shares will be deemed cancelled and will represent only the right to receive the Redemption Amount.

Vaccinex Announces Pricing of $9.6 Million Public Offering

Retrieved on: 
Friday, September 29, 2023
Exercise, Telephone, Neurodegenerative disease, Cancer, Managed file transfer, Sale, Prospectus, Form S-1, Form, Madison Avenue, Security (finance), SEMA4D

The closing of the offering is expected to occur on or about October 3, 2023, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about October 3, 2023, subject to the satisfaction of customary closing conditions.
  • The gross proceeds from the offering are expected to be approximately $9.6 million.
  • A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
  • The offering is being made only by means of a prospectus forming part of the effective registration statement.

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering

Retrieved on: 
Thursday, September 28, 2023
Exercise, Therapy, ThinkEquity, Cancer, File hosting service, RNA, Sale, Prospectus, Form S-1, Form, Security (finance)

Each share of common stock (or Pre-Funded Warrant) was sold at a public offering price of $0.51 per share (inclusive of the Pre-Funded Warrant exercise price of $0.01 per share).

Key Points: 
  • Each share of common stock (or Pre-Funded Warrant) was sold at a public offering price of $0.51 per share (inclusive of the Pre-Funded Warrant exercise price of $0.01 per share).
  • All of the shares and Pre-Funded Warrants in the offering were sold by the Company.
  • Total gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $8.5 million.
  • The offering was made only by means of a prospectus forming part of the effective registration statement relating to the offering.